Study: NCT04198766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-106 - Hexavalent OX40 agonist antibody
Description: The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-106 - Hexavalent OX40 agonist antibody
Description: The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-106 - Hexavalent OX40 agonist antibody
Description: The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-106 - Hexavalent OX40 agonist antibody
Description: The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-106 - Hexavalent OX40 agonist antibody
Description: The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INBRX-106 - Hexavalent OX40 agonist antibody
Description: The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-106 - Hexavalent OX40 agonist antibody
Description: The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-106 - Hexavalent OX40 agonist antibody
Description: The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-106 - Hexavalent OX40 agonist antibody
Description: The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-106 - Hexavalent OX40 agonist antibody
Description: The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-106 - Hexavalent OX40 agonist antibody
Description: The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-106 - Hexavalent OX40 agonist antibody
Description: The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-106 - Hexavalent OX40 agonist antibody
Description: The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg
Description: pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg
Description: pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg
Description: pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg
Description: pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg
Description: pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg
Description: pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg
Description: pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg
Description: pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg
Description: pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg
Description: pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab 400 mg
Description: pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab 400 mg
Description: pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC-5
Description: carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC-6
Description: carboplatin AUC-6 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m2
Description: pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m2
Description: pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 75mg/m2
Description: cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200mg/m2
Description: paclitaxel 200mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel 100mg/m2
Description: Nab paclitaxel 100mg/m2 by intravenous (IV) infusion, given on Days 1, 8 and 15 of each 21-day cycle of cycles 1-4